Evermay Wealth Administration LLC trimmed its place in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 10.6% throughout the third quarter, in line with the corporate in its most up-to-date submitting with the SEC. The institutional investor owned 8,520 shares of the corporate’s inventory after promoting 1,012 shares throughout the interval. Evermay Wealth Administration LLC’s holdings in Johnson & Johnson had been price $1,381,000 on the finish of the latest reporting interval.
Different institutional traders and hedge funds have additionally just lately added to or diminished their stakes within the firm. Innealta Capital LLC bought a brand new place in Johnson & Johnson throughout the 2nd quarter price roughly $27,000. Highline Wealth Companions LLC bought a brand new place in Johnson & Johnson throughout the third quarter price roughly $31,000. Mowery & Schoenfeld Wealth Administration LLC grew its holdings in shares of Johnson & Johnson by 58.7% throughout the third quarter. Mowery & Schoenfeld Wealth Administration LLC now owns 246 shares of the corporate’s inventory valued at $40,000 after buying a further 91 shares within the final quarter. Morton Brown Household Wealth LLC grew its holdings in shares of Johnson & Johnson by 400.0% throughout the third quarter. Morton Brown Household Wealth LLC now owns 250 shares of the corporate’s inventory valued at $41,000 after buying a further 200 shares within the final quarter. Lastly, MFA Wealth Advisors LLC bought a brand new place in shares of Johnson & Johnson throughout the 2nd quarter valued at $43,000. 69.55% of the inventory is presently owned by hedge funds and different institutional traders.
Wall Avenue Analysts Forecast Development
A number of equities analysts have just lately commented on JNJ shares. Sanford C. Bernstein boosted their value goal on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. StockNews.com upgraded shares of Johnson & Johnson from a “purchase” ranking to a “strong-buy” ranking in a report on Saturday, September 14th. Daiwa Capital Markets minimize shares of Johnson & Johnson from an “outperform” ranking to a “impartial” ranking and lowered their value goal for the corporate from $160.00 to $150.00 in a report on Tuesday, July twenty third. Wells Fargo & Firm boosted their value goal on shares of Johnson & Johnson from $163.00 to $166.00 and gave the corporate an “equal weight” ranking in a report on Wednesday, October sixteenth. Lastly, Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” ranking to a “maintain” ranking in a analysis notice on Tuesday, July twenty third. Six equities analysis analysts have rated the inventory with a maintain ranking, seven have given a purchase ranking and one has assigned a powerful purchase ranking to the corporate’s inventory. Primarily based on knowledge from MarketBeat, Johnson & Johnson presently has a consensus ranking of “Reasonable Purchase” and a median goal value of $175.93.
Get Our Newest Report on Johnson & Johnson
Johnson & Johnson Inventory Down 0.5 %
Johnson & Johnson inventory opened at $159.86 on Friday. The agency has a market cap of $384.88 billion, a price-to-earnings ratio of 23.13, a P/E/G ratio of two.90 and a beta of 0.52. The corporate has a debt-to-equity ratio of 0.44, a present ratio of 1.07 and a fast ratio of 0.85. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week excessive of $168.85. The agency has a fifty day transferring common value of $163.39 and a two-hundred day transferring common value of $155.35.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final launched its earnings outcomes on Tuesday, October fifteenth. The corporate reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The agency had income of $22.47 billion throughout the quarter, in comparison with analyst estimates of $22.17 billion. Johnson & Johnson had a web margin of 19.14% and a return on fairness of 35.46%. The enterprise’s income was up 5.2% on a year-over-year foundation. Throughout the identical quarter within the earlier yr, the enterprise earned $2.66 EPS. As a gaggle, analysts forecast that Johnson & Johnson will submit 9.94 earnings per share for the present yr.
Johnson & Johnson Dividend Announcement
The enterprise additionally just lately disclosed a quarterly dividend, which will probably be paid on Tuesday, December tenth. Stockholders of document on Tuesday, November twenty sixth will probably be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized foundation and a dividend yield of three.10%. The ex-dividend date is Tuesday, November twenty sixth. Johnson & Johnson’s dividend payout ratio is presently 71.78%.
Insider Exercise
In different information, VP Robert J. Decker bought 5,635 shares of the corporate’s inventory in a transaction dated Friday, August thirtieth. The shares had been bought at a median value of $165.06, for a complete transaction of $930,113.10. Following the completion of the transaction, the vp now owns 18,973 shares of the corporate’s inventory, valued at roughly $3,131,683.38. This represents a 0.00 % lower of their possession of the inventory. The sale was disclosed in a submitting with the Securities & Alternate Fee, which is accessible by way of the SEC web site. 0.16% of the inventory is owned by firm insiders.
Johnson & Johnson Firm Profile
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells numerous merchandise within the healthcare area worldwide. The corporate’s Revolutionary Medication section affords merchandise for numerous therapeutic areas, akin to immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious ailments comprising HIV/AIDS; neuroscience, consisting of temper issues, neurodegenerative issues, and schizophrenia; oncology, akin to prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension by way of retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Learn Extra
Need to see what different hedge funds are holding JNJ? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Obtain Information & Scores for Johnson & Johnson Every day – Enter your e-mail deal with beneath to obtain a concise day by day abstract of the most recent information and analysts’ scores for Johnson & Johnson and associated corporations with MarketBeat.com’s FREE day by day e-mail publication.
